Canget BioTekpharma (United States)

Recent papers from Canget BioTekpharma (United States)

1. FL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combinationJournal of Experimental & Clinical Cancer Research · 2025
2. Targeted Treatment of Sarcomas by Single Protein Encapsulated Doxorubicin with Undetectable Cardiotoxicity and Superior EfficacyCancers · 2025
3. Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancerJournal of Pharmaceutical Analysis · 2024
4. Structure–Activity Relationship of FL118 Platform Position 7 Versus Position 9-Derived Compounds and Their Mechanism of Action and Antitumor ActivityJournal of Medicinal Chemistry · 2023
5. Single protein encapsulated SN38 for tumor-targeting treatmentJournal of Translational Medicine · 2023
6. Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influenceSHILAP Revista de lepidopterología · 2023
7. Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative DiseasesInternational Journal of Molecular Sciences · 2022
8. FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacyClinical and Translational Medicine · 2022
9. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinomaSHILAP Revista de lepidopterología · 2021
10. Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder CancerCancers · 2020
11. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?Journal of Experimental & Clinical Cancer Research · 2019
12. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancerJournal of Experimental & Clinical Cancer Research · 2018